Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

AACR 2009: Frequent JAK Mutations in Pediatric Acute Lymphoblastic Leukemia (ALL) with Poor Outcome: A New Therapeutic Target in Resistant Disease

AACR 2009

18 - 22 Apr 2009

Published: 30 Apr 2009

Views: 14797

Rating:

Save

Dr Charles Mullighan - Department of Pathology, St Jude Children's Research Hospital

Charles Mullighan, M.B.B.S. (Hons), M.Sc., M.D., assistant member, department of pathology, St. Jude Children’s Research Hospital presents at the 2009 AACR conference in Denver: Frequent JAK Mutations in Pediatric Acute Lymphoblastic Leukemia (ALL) with Poor Outcome: A New Therapeutic Target in Resistant Disease

Related Videos

Blinatumomab added to chemotherapy improves disease-free survival in newly...

Dr Rachel Rau - University of Washington, Seattle, USA

Blinatumomab added to chemotherapy improves disease-free survival in newly diagnosed NCI standard risk paediatric B-ALL ( Dr Rachel Rau - University of Washington, Seattle, USA )

IRANCANSURV: Dissecting the variances in childhood cancer survival across Iran

Dr Saeed Nemati - International Agency for Research on Cancer , Lyon, France

IRANCANSURV: Dissecting the variances in childhood cancer survival across Iran ( Dr Saeed Nemati - International Agency for Research on Cancer , Lyon, France )

New classification for identifying HR myeloma based on cytogenetic abnormalities

Dr Jill Corre - IUCT Oncopole, Toulouse, France

New classification for identifying HR myeloma based on cytogenetic abnormalities ( Dr Jill Corre - IUCT Oncopole, Toulouse, France )

Daratumumab, bortezomib/thalidomide/dexamethasone (D-VTd) and DARA maintenance...

Dr Jill Corre - IUCT Oncopole, Toulouse, France

Daratumumab, bortezomib/thalidomide/dexamethasone (D-VTd) and DARA maintenance shows benefit in transplant-eligible NDMM ( Dr Jill Corre - IUCT Oncopole, Toulouse, France )

Made to measure: Choosing the optimal regimen in transplant-eligible NDMM

Dr Elias Mai - Heidelberg University, Heidelberg, Germany

Made to measure: Choosing the optimal regimen in transplant-eligible NDMM ( Dr Elias Mai - Heidelberg University, Heidelberg, Germany )

Revolutionising myeloma treatment through immune profiling

Dr Romanos Sklavenitis-Pistofidis - Dana-Farber Cancer Institute, Boston, USA

Revolutionising myeloma treatment through immune profiling ( Dr Romanos Sklavenitis-Pistofidis - Dana-Farber Cancer Institute, Boston, USA )

Treating relapsed multiple myeloma outside of use of T-cell redirected therapies

Prof Joy Ho - The University of Sydney, Sydney, Australia

Treating relapsed multiple myeloma outside of use of T-cell redirected therapies ( Prof Joy Ho - The University of Sydney, Sydney, Australia )

Guiding transplant decisions in multiple myeloma with MRD

Dr Susan Bal - University of Alabama at Birmingham, Birmingham, USA

Guiding transplant decisions in multiple myeloma with MRD ( Dr Susan Bal - University of Alabama at Birmingham, Birmingham, USA )

Revolutionising multiple myeloma treatment with CAR T-Cell therapies

Dr Susan Bal - University of Alabama at Birmingham, Birmingham, USA

Revolutionising multiple myeloma treatment with CAR T-Cell therapies ( Dr Susan Bal - University of Alabama at Birmingham, Birmingham, USA )

More from ecancer